ProPharma Group Develops New RCO Model for Biotech, Pharmaceutical, and Medical Device Industries

In January 2023, ProPharma Group, the world's largest research consulting organization (RCO) for companies in the pharmaceutical, biotechnology, and medical device industries, launched its bespoke model to soar beyond the traditional CRO.



This new type of research consulting and clinical service for biotech, pharma, and device innovators delivers solutions that bring life-saving drugs to market sooner and more cost-effectively. Traditional CROs are rigid and apply a "best fit" approach across biopharma companies. With shifting healthcare landscapes and changing regulations, it's never been more important to offer personalization and agility to biotech, pharma, and medical device companies.



Smaller and mid-size companies, or those that focus on a specific or rare disease, have been left behind by the rigidity of traditional CROs. These life-saving companies find themselves ignored by CROs, who feel "the bigger, the better." With changing market needs, ProPharma Group saw an opportunity for the healthcare industry to embrace a new service partner: research consulting organizations.



Today's pharmaceutical companies need research partners to develop and commercialize their products -- and not necessarily cheaper, better, and faster as a mantra by traditional CROs. ProPharma's new RCO model is a more thoughtful approach that looks at risk, options, and quality to support a product's entire lifecycle. Whereas CROs have a cookie-cutter agenda, ProPharma's bespoke model supports smaller biopharma companies who have been left out by the traditional model. They offer customized solutions scaled to a company's size and are constantly innovating to support current market needs.



With over 2,500 professionals and more than 1,000 clients, ProPharma Group is the leader in regulatory sciences, clinical research solutions, quality and compliance, pharmaceutical solutions, medical information, and R&D technology.